Selective removal of plasma components by high-performance immunoaffinity chromatography

Area of Science:

• Biomedical Engineering
• Immunochemistry
• Analytical Chemistry

Background:

• Amyloid deposition in dialysis patients is a significant clinical challenge.
• Current methods for removing specific plasma components are limited.
• Immunoaffinity chromatography (IAC) offers high specificity for biomolecule isolation.

Purpose of the Study:

• To develop and evaluate high-performance immunoaffinity chromatography (HPIAC) for removing beta2-microglobulin.
• To investigate the use of membranes as affinity ligand supports for extracorporeal circulation.
• To assess the biocompatibility and efficacy of antibody-bearing immunoaffinity membranes.

Main Methods:

• HPIAC was employed to specifically remove beta2-microglobulin from human plasma.
• Antibodies immobilized on membranes were utilized in an extracorporeal circulation system (ECS).
• Removal of rat immunoglobulin E and human serum amyloid P component was studied.
• Nonspecific binding of plasma components to the immunoaffinity membrane was assessed.

Main Results:

• HPIAC demonstrated high efficacy in removing beta2-microglobulin from human plasma.
• Immobilized antibodies on membranes effectively removed target proteins (rat IgE, human SAP) via ECS.
• The immunoaffinity membrane exhibited good biocompatibility with minimal nonspecific binding.

Conclusions:

• HPIAC is a rapid and specific method for isolating and removing target molecules from plasma.
• Immunoaffinity membranes integrated into ECS show potential for therapeutic removal of unwanted plasma components.
• These techniques have broad applicability for managing various medical conditions involving plasma component imbalances.